NEW YORK (GenomeWeb) – Investment bank Leerink Partners today said it has downgraded Bruker's stock to Market Perform from Outperform based on expectations that margin expansion will be more difficult than is indicated by the current stock price.

Bruker's stock has appreciated 55 percent in the past year compared to no appreciation for the S&P 500, wrote Leerink analyst Dan Leonard in his note today. Leerink believes "the large, discrete activities for margin expansion are in the rear view mirror," he added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.